The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults.
>10%: Local: Application-site pain (≤12%)
1% to 10%:
Local: Application-site dermatitis (≤3%), application-site edema (≤2%), application-site erythema (5% to 6%), application-site pruritus (2% to 4%), application-site vesicles (≤1%), local skin discoloration (≤1%; application site), local skin exfoliation (≤3%; application site)
Miscellaneous: Fever (2%)
<1%:
Dermatologic: Skin erosion (application site)
Local: Application-site irritation
There are no contraindications listed in the manufacturer's labeling.
Zelsuvmi: FDA approved January 2024; availability anticipated in 2024.
Molluscum contagiosum: Treatment of molluscum contagiosum in adults and pediatric patients ≥1 year of age.
None known.
There are no known significant interactions.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟